Illumina, based in San Diego, announced it will acquire SomaLogic, a specialist in data-driven proteomics, for $350 million in cash at closing, along with up to $75 million in performance‑based payments, according to the company. The acquisition, expected to close in the first half of 2026 pending regulatory approval, is aimed at accelerating Illumina’s multi‑omics strategy and expanding its footprint in the growing proteomics market.
Illumina and SomaLogic have worked together since December 2021 to integrate SomaLogic’s SomaScan® Proteomics Assay with Illumina’s high‑throughput next‑generation sequencing (NGS) platforms. Illumina said the deal will enhance capabilities for biomarker discovery and disease profiling, combining SomaLogic’s protein measurement technology with Illumina’s NovaSeq X, DRAGEN™ software, and Connected Multiomics ecosystem.
The company claims that nearly 40 early‑access customers are already using Illumina Protein Prep, with broader availability planned for Q3 2025 . Illumina added that SomaLogic’s aptamer‑based affinity platform and kitted NGS consumables are expected to be profitable on a non‑GAAP basis by 2027, with margins aligning with Illumina by 2028.
SomaLogic operates out of Boulder, Colorado, employing about 250 staff across commercial, R&D, and manufacturing. Its Boulder lab, which is CLIA‑ and CAP‑certified, will be included in the deal . Illumina noted that until the acquisition closes, both companies will continue to operate independently.
Completion of the acquisition depends on customary conditions, including regulatory clearance under the Hart‑Scott‑Rodino Act
